Cancer Biopsy Market Report and Forecast 2024-2032

Cancer Biopsy Market Outlook

The cancer biopsy market size in the major markets was valued at USD 28.7 billion in 2023, driven by the incidence of cancer cases across the 7 major markets. The market is expected to grow at a CAGR of 13.2% during the forecast period of 2024-2032, with the values likely to rise from USD 32.5 billion in 2024 to USD 87.4 billion by 2032.

Cancer Biopsy: Introduction

Cancer Biopsy is a type of diagnostic method to detect the presence of a tumour in a body part. It is done by removing a piece of tissue or a sample of cells from the body to test externally in a lab. If cancer exists, a biopsy can help in the determination of its grade. Doctors mostly prescribe it if a patient shows underlying signs of cancer like weakness or fatigue.

After taking the tissue sample, it is sent to a laboratory where it can be chemically treated or frozen and sliced into thin sections. These sections are later placed on glass slides and studied under a microscope. There are different types of biopsies like needle biopsies, skin biopsies, endoscopic biopsies, and others.

Cancer Biopsy Market Analysis

Cancer is one of the most fatal diseases, affecting a substantial portion of the population. As there has been significant emphasis on treatment, early diagnosis plays a critical role in decreasing the number of mortalities related to it. Therefore, the cancer biopsy market demand has increased over the years.

Over the years, liquid biopsy has been a preferred method of detection when compared to conventional technology. This can be attributed to its safe, non-invasive, and easily recurring process. With a vision to expand the potential of liquid biopsy to detect and monitor cancer, researchers at the AACR annual meeting 2023 presented a study of an MCED test which utilizes a new platform to analyze DNA methylation. This new platform captures methylated cfDNA without any prior chemical treatment, which leads to easy distinguishing between cancer and non-cancer cells with high precision.

Researchers at Breast Cancer Research Foundation also developed HDSCA 3.0, the novel third-generation liquid biopsy technology, that uses five distinct biomarkers to identify and detect rare circulating cells. In addition, early-stage lung cancer detection has also observed significant advancements. For example, Biomark’s blood based metabolomic biomarker panel got clinically approved by the FDA in June 2023. The cancer biopsy market growth is certain, owing to the holistic research in developing better diagnostic solutions in cancer.

Cancer Biopsy Market Segmentation

Market Breakup by Product and Services

• Kits and Consumables

• Instruments

• Services

Market Breakup by Type

• Needle Biopsy

• Skin Biopsies

• Bone Marrow Biopsies

• Liquid Biopsies

• Other Biopsies

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Cancer Biopsy Market Overview

Cancer is the second most prevalent chronic illness after cardiovascular diseases in the United States, as a result, it has dominated the cancer biopsy market share in the historical period. The presence of key medical industry pioneers along with a robust infrastructure and relevant awareness on diagnostics has contributed to the market share.

During the forecast period, EU-4 is anticipated to lead the major markets as there are some major developments occurring in the region. For instance, Hungary has become a hub of artificial intelligence led technologies to detect cancer at an early stage, which is set to revolutionize the entire diagnostic market. Moreover, the Welsh government launched a new diagnostic strategy in Wales to lower the burden of lung cancer in the region.

Asia Pacific, especially Japan, is expected to witness the fastest growth which can be accredited to an intense emphasis on providing relevant awareness to the people to prevent cancer cases. Hence, the cancer biopsy market size will expand. In addition, there are several research and development initiatives to drive contemporary innovations in the field, aiding growth in upcoming years.

Cancer Biopsy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• QIAGEN

• Illumina, Inc.

• ANGLE plc

• BD (Becton, Dickinson and Company)

• Bio-Rad Laboratories Inc.

• Hologic, Inc.

• BIOCEPT, INC. 

• Thermo Fisher Scientific, Inc.

• F. Hoffmann-La Roche Ltd.

• Danaher

Key Highlights of the Report